When should HBV therapy be modified: differences between drugs and risk for resistance development
Text Box: Risk for selection of HBV resistance-associated mutatWahrscheinlichkeit der Selektion Reions (%)
Risk for selection of HBV resistance-associated mutatWahrscheinlichkeit der Selektion Reions (%)
time (months under therapy)
Nukleos(t)ide-Analogues treatment-naive patients
Lamivudine
Telbivudine
Adefovir
ETV                                TDF